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Abstract The heart relies mainly on mitochondrial metab-
olism to provide the energy needed for pumping blood
to oxygenate the organs of the body. The study of
mitochondrial function in the human heart faces many
obstacles and elucidation of the role of mitochondria in
cardiac diseases has relied mainly on studies with animal
models. Cardiac diseases are the leading cause of mortality
worldwide. With the emergence of new therapies to treat
and prevent heart disease, some aiming at metabolic
modulation, a need for acquiring a better understanding of
mitochondrial function in the human heart becomes
apparent. Our review is aimed at specific evaluation of the
human heart in terms of (1) methods to understand
mitochondrial function, with particular emphasis on inte-
grated function, (2) data on the role of mitochondrial
dysfunction in cardiovascular disease, and (3) possible
applications of this knowledge in the treatment of patients
with cardiac disease.
Keywords Oxidative phosphorylation . Electron transport
complexes . Heart failure .Mitochondrial defect .
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Introduction
The rhythmic contraction of the heart ensures oxygenation of
the organs of the body. Most of the energy needed for this
arduous task is provided by mitochondrial metabolism,
which produces a high-energy molecule, adenosine triphos-
phate (ATP). The process of energy production by mito-
chondria is called oxidative phosphorylation (OXPHOS),
because it involves the coupling of oxygen to phosphoryla-
tion of ADP into ATP. The human heart daily synthesizes
approximatively 30 kg of ATP (Ferrari et al. 2006).
In the failing heart, a decrease in energy reserves has
been measured by phosphorus-31 NMR spectroscopy. This
technique facilitates in vivo exploration of intracellular
metabolism. A low phosphocreatine-to-ATP ratio (PCr/
ATP), indicating a cardiac energy deficit, has been shown
in the failing human heart (Beer et al. 2002; Conway
et al. 1991; Hardy et al. 1991; Neubauer et al. 1997;
Neubauer et al. 1992). This ratio is correlated with clinical
symptoms (Conway et al. 1998) and predicts mortality
better than the left ventricular ejection fraction (Neubauer
et al. 1997). As the main energy source, mitochondria are
suspected to be at least in part responsible for the low
energy reserve in the failing heart (Mettauer et al. 2006).
The NMR approach, however, does not reveal intrinsic
mitochondrial content or function, even if it often has been
interpreted as such.
Little information is available on mitochondrial function
in the human heart. Most of the studies on the role of
mitochondria in cardiac diseases have relied on animal
models, which may not be representative of the human.
However, tissue samples of the human heart are routinely
removed in standard surgery (atrium cannulation, heart
transplantation, cardiac biopsies), providing a resource that
is underutilized for research on mitochondrial physiology
and pathophysiology. The development of new methods to
study mitochondrial function provides an opportunity to
use the small amount of tissue available from routine
surgeries to understand mitochondrial function. Our review
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is aimed at evaluating (1) the different methods available to
understand mitochondrial function in the human, (2) the
state of knowledge of the role of mitochondrial dysfunction
in heart diseases, and (3) the possibility of applying
this knowledge in the treatment of patients with cardiac
diseases.
Methods to study human heart mitochondria
OXPHOS involves several interacting pathways. As a first
step, most substrates for mitochondrial metabolism enter by
transporters and are metabolized to produce reducing
equivalents, usually through the action of dehydrogenases.
For example, pyruvate is transported by the monocar-
boxylate transporter and dehydrogenated by the pyruvate
dehydrogenase complex in the matrix, generating NADH
and acetyl CoA. Fatty acids are transported by a complex
carnitine transporter system and then go through beta-
oxidation to generate NADH, FADH2, and acetyl CoA
(Kerner and Hoppel 2000). The TCA cycle, which
produces NADH and FADH2, funnels electrons into the
electron transport complexes (ETC). The electron transport
system is composed of four ETC: Complexes I (CI, NADH-
ubiquinone oxidoreductase), II (CII, succinate ubiquinone
oxidoreductase), III (CIII, ubiquionol-cytochrome c oxido-
reductase), and IV (CIV, cytochrome c oxidase), and two
main electron carriers (ubiquinone and cytochrome c). The
transfer of electrons through three complexes coupled to the
pumping of protons into the space between the inner and
outer mitochondrial membranes creates a proton gradient,
which drives the ATP synthetase in the inner membrane to
produce ATP. The other substrates for the ATP synthetase
are transported through the mitochondrial inner membrane
by the adenine nucleotide translocase (ANT) and the
phosphate carrier. The resulting matrix ATP is transported
into the intermembrane space by ANT where mitochondrial
creatine kinase (CK) catalyzes the transfer of the high-
energy phosphate to creatine, which is stored in the form
of cytosolic PCr for later use by the cardiac fibers for
contraction.
Impaired mitochondrial function may be related to any
steps involved in this complex process, either in term of the
quantity, the concentration, or the functionality of the
different components, or their interaction. Even in the face
of the pivotal importance of mitochondrial energy produc-
tion in the human heart, mitochondrial function unfortu-
nately has not been studied in any depth. This part of
the mini-review is aimed at providing a summary of the
different methods available to enhance our knowledge of
mitochondrial pathophysiology. Particular emphasis will be
placed on methods allowing the measurement of integrated
mitochondrial functions.
Activities of mitochondrial enzymes
In attempts to identify possible causes for a decline in
mitochondrial function in diseased hearts, most studies
have focused on the measurement of enzyme activities (EA,
Table 1). The spectrophotometric assays for enzyme
activities can be performed on isolated mitochondria, but
the majority of the studies used homogenates of tissue,
especially when the amount of tissue available was too
small for isolation of mitochondria. Tissues or mitochondria
can be used fresh or frozen for analysis, but some enzymes
lose activity if frozen (Rustin et al. 1994). The measure-
ment of mitochondrial enzyme activities yields valuable
information about the capacity of some steps involved in
mitochondrial metabolism, but has an important limitation
when the objective is to evaluate the capacity of energy
production by the whole system. The measurements are
performed in mitochondria with permeabilized inner mem-
brane, removing the transport barriers. Furthermore, the
complex regulation of OXPHOS in vivo is not taken into
account. For example, CIII and CIV are known to be
present in amounts larger than needed to support the
maximal electron flow in the ETC in human skeletal
muscle (Kunz et al. 2000) and in human cells (Villani and
Attardi 1997; Villani et al. 1998). The functional impair-
ment in the pathway appears only when the capacity of the
enzyme is reduced below the threshold activity (Rossignol
et al. 2003). The excess capacity is highly variable in
different tissues and species (Rossignol et al. 2000) and is
unknown in the human heart. Thus, an apparent reduction
in the activity of single step may have no effect on the
whole process.
Integrated mitochondrial function-OXPHOS
To understand the effect of mitochondrial dysfunction in
the pathophysiology of the human heart, a more integrative
approach is to look at the process of OXPHOS by
polarographic measurement of oxygen consumption in
mitochondria in the presence of specific substrates that
feed electrons into different sites of the ETC (Puchowicz et
al. 2004). For example, in the presence of pyruvate +
malate or succinate (+rotenone), the electrons fed into CI or
CII, are transferred to ubiquinone, CIII, and CIV, where
oxygen plus hydrogen are converted into water. Substrates
derived from carbohydrate, amino acids, or fatty acids
oxidation can be used to evaluate mitochondrial function.
Oxygen consumption in the presence of ADP is coupled to
the production of ATP by the phosphorylation system. The
measurement of oxygen consumption in the absence of
ADP (or after its complete consumption) is used as an
estimation of the proton leak, i.e., the protons not used to
phosphorylate the ADP. Uncouplers also can be added to
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dissociate the proton gradient in the intermembrane space
and to look at the limitation of the electron transport by the
phosphorylation system. The measurement of OXPHOS
assesses multiple components of mitochondrial metabolism
and can uncover defects and differences in mitochondrial
function not apparent by other techniques.
Isolated mitochondria
The conventional measurement of OXPHOS is performed
after isolation of mitochondria from fresh tissue. The entire
population of heart mitochondria can be isolated as a whole
or, if the amount of tissue is sufficient, the subsarcolemmal
and interfibrillar mitochondrial populations can be har-
vested separately (Palmer et al. 1977). The two populations
have been shown to be differentially affected in an animal
model of cardiomyopathy (Hoppel et al. 1982). The
subpopulations of mitochondria were separated in cardiac
tissue from patients undergoing a mitral valve replacement
(Weinstein et al. 1986), but no information is available at
present on the involvment of those populations per se on
human cardiac pathophysiology.
The differential isolation of mitochondrial subpopula-
tions requires a substantial amount of tissue available from
the explanted heart of patients undergoing transplantation,
but the roadblock is the difficulty in obtaining tissue from
control healthy human heart. In enzymatic or genetic
studies, autopsy samples often are used as controls (Table 1,
groups CA), but they are, in some cases, taken several
hours after death and cannot be used for OXPHOS
measurements. A control group for OXPHOS measured in
isolated mitochondria depends mostly on the availability of
scarce donor hearts for transplantation that for some reason
end up not being used.
Permeabilized fibers
The permeabilized fiber method (Veksler et al. 1987) allows
the analysis of mitochondrial function in only a few milli-
grams of muscle tissues. Based on the selective perme-
abilization of the sarcolemma by mechanical separation with
forceps and by exposure to a low concentration of saponin,
the mitochondria can be studied in their cellular environment,
depleted of cytosol, but with a functionally and morpho-
logically intact architecture (Kunz et al. 1993; Kuznetsov et
al. 2008; Saks et al. 1998). As for isolated mitochondria,
different substrates, inhibitors, and uncouplers can be used
to assess the OXPHOS pathway. With permeabilized myo-
cardial bundles, both subsarcolemmal and interfibrillar mito-
chondrial populations are evaluated (Veksler et al. 1987).
This technique offers several advantages for the study of
the human heart because it is possible to make measure-
ments on very small amounts of tissue taken 1) during
cardiac biopsy, e.g., for the follow up of rejection criteria in
patients after a heart transplantation, 2) during routine
surgery, e.g., removal of the atrial appendage (or part of it)
before cannulation of the atrium and 3) from the donor
heart when implanted into the recipient, overcoming the
major problem of lack of control group in many studies.
This technique is particularly attractive in combination
with high-resolution respirometry (Oroboros, Innsbruck,
Austria), making it possible to detect small differences in
respiratory function. A possible limitation of this method is
that sensitivity of respiration in response to the addition of
substrates or inhibitors can be altered by inadvertent
inclusion of non-mitochondrial structures such as myo-
fibrillae and cells of non-myocyte origin, but the bias exists
for normal and sick patients alike. Furthermore, the hetero-
geneity of structures in the tissues may lead to more vari-
ability between replicate measurements on different pieces
of myocardial tissue from the same patient.
Anatomical sites in the heart
Another important problem in the study of the human heart
is the different myocardial anatomical sites that are used as
sources during diverse surgeries, with different chambers
available from the explanted heart during transplantation
(left and right atrium and ventricles), from surgeries
requiring cardiopulmonary bypass (right atrial appendage),
from biopsies (interventricular septum), and from the donor
heart (left atrium). In end-stage heart failure (HF) patients
undergoing transplantation, the rate of respiration in fibers
per mg protein (Sharov et al. 2000) or in isolated mito-
chondria per mg mitochondrial protein (Lee et al. 1998)
was similar in both ventricles. In fibers from atrial
appendages, the respiration rate with all substrates is lower
compared to ventricles, showing the decrease in mitochon-
drial content, but when OXPHOS was corrected for the
amount of mitochondria (using the maximum uncoupled
respiration) the respiration was similar in the three
chambers (Lemieux et al. 2008).
The importance of studies focused on the mitochondrial
function in the human heart
Animal models are of great utility for the study of
cardiomyopathies and HF, but such studies may not explain
the mitochondrial defect occurring in the failing human
heart. The first reason is the major differences in history of
the disease and degree of decompensation between animals
and humans (Scheubel et al. 2002). A second could be the
special features of human heart mitochondria (vida infra).
Compared to human skeletal muscle, the activity of citrate
synthase (CS) is three-fold higher in the human heart (18.6
and 58.6 umol/min/g tissue for skeletal muscle and heart,
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respectively, unpublished data), in accordance with a three-
fold increase in activity of CI, CII, CIII (unpublished data).
The respiration rate of the human left ventricle is similar to
human skeletal muscle (reviewed by (N’Guessan et al.
2004), and lower in the cardiac atrial appendage (Gellerich
et al. 1994). With more mitochondria and more ETC
activity in the human heart compared to skeletal muscle,
why is the OXPHOS capacity not higher? Part of the
explanation comes from the impressive limitation of
OXPHOS capacity by the phosphorylation system in
human heart mitochondria. The respiration coupled to the
production of ATP was about 40% of the maximal capacity
of the electron transport (measured after uncoupling) in the
human heart (Lemieux et al. 2008) compared to 80% in the
human skeletal muscle (Boushel et al. 2007). In mice and
rats, however, OXPHOS capacity is much higher in heart
compared to skeletal muscle, and the phosphorylation
system in both tissues exerts almost no limitation on
maximal OXPHOS capacity (Aragonés et al. 2008;
Lemieux et al. 2006). Calcium accumulation by human
heart mitochondria also was shown to be lower than in the
hearts of a variety of animals (Lindenmayer et al. 1971).
These examples showed the particularities of the human
heart mitochondria that can be seen only by studying
OXPHOS. It reinforces the importance of achieving a
better understanding of the regulation of mitochondrial
metabolism specifically in the human heart.
Mitochondrial dysfunctions in human
heart: current knowledge
Table 1 presents an overview of knowledge of mitochon-
drial dysfunctions, enzyme activities, and OXPHOS in
diseases of the human heart. Most of these studies concern
HF, a complex, multifactorial syndrome resulting in the
chronic and progressive loss of ventricular function leading
to both cardiac and systemic perturbations. A number of
underlying causes can lead to HF, including ischemic heart
disease (coronary heart disease, myocardial infarction,
and hypertension), cardiomyopathy (dilated, hypertrophic),
valvular disease, and alcohol/drug-induced heart disease. In
general, HF is preceded by an initial insult, e.g., cardio-
myocyte loss or persistently increased workload, which
activates compensatory mechanisms such as hypertrophy.
In the short term, the compensation apparently restores
cardiovascular function but the sustained activation of
compensatory mechanisms can lead to secondary heart
damage, i.e., deleterious alterations in ventricular mass,
chamber size, and shape, leading to incapacity of the heart
to meet the needs of the body (Latronico et al. 2008).
Most of the previous studies on mitochondrial function
in human HF compared donor hearts with hearts from
patients at end-stage HF at the time of transplantation
(Table 1, ES groups, most of them in class III or IV of the
New York Heart Association). End-stage HF was associated
with multiple mitochondrial functional injuries, e.g., a
decrease of ETC activities per muscle mass, most notably
CI (Scheubel et al. 2002), CIII (Buchwald et al. 1990;
Jarreta et al. 2000; Marin-Garcia et al. 1995), and CIV
(Arbustini et al. 1998; Quigley et al. 2000), and a decrease
in OXPHOS capacity in the presence of substrates directing
electrons into CI in permeabilized fibers (Saks et al. 1991;
Sharov et al. 2000). Part of the loss of mitochondrial ETC
activity or OXPHOS per g of muscle is explainable by a
decrease in mitochondrial content occurring also in end-
stage HF (Kalsi et al. 1999; Nascimben et al. 1996; Quigley
et al. 2000). The similarity in CS activity between end-stage
HF and control groups (Maurer and Zierz 1994) may be
explained by the age differences between groups, because
the CS activity increases with age (Marin-Garcia et al.
1998). The decrease in mitochondrial content is not the
only defect occurring in severe HF as the activity of CI
(Scheubel et al. 2002) and CIII (Jarreta et al. 2000)
expressed over the CS activity also significantly decreased.
It previously has been suggested that mitochondrial
uncoupling occurs in HF patients. This uncoupling may
offer a cardioprotective effect, reducing ROS production
(Chen et al. 2007), but also would result in a further loss of
cardiac efficiency by allowing protons to re-enter the matrix
without ATP synthesis (Murray et al. 2007). The proposed
uncoupling in heart disease is supported by increased
cardiac levels of uncoupling protein 3 in patients under-
going coronary artery bypass surgery (Murray et al. 2004).
While the decrease in respiratory control in end-stage HF
has been used in support of uncoupling (Murray et al.
2007), the decrease in respiratory control is explained by
the decrease in State 3 respiration rather than by an increase
in leakage (Sharov et al. 2000); this is not uncoupling.
Other evidence also shows that coupling is preserved in HF
mitochondria (Chidsey et al. 1966) even at a late stage of
the disease (Lemieux et al. 2008).
A disturbance of the phophorylation system also occurs
in severe HF. In dilated cardiomyopathy, an upregulation
(Sylven et al. 1993) and an increase in concentration
(Schultheiss 1992) of the ANT carrier has been shown. This
carrier upregulation, however, was associated with a de-
crease in function (Dörner et al. 2006; Dörner et al. 1997;
Schultheiss 1992), explained by a change in the expression
pattern of the ANT isoforms, i.e., increase in ANT1 and
decrease in ANT2 (Dörner et al. 2006; Dörner and
Schultheiss 2000; Dörner et al. 1997). ATPase activity also
has been shown to be decreased in the failing human heart,
but at least part of the decrease is explained by the decrease
in mitochondrial content (Unverferth et al. 1988). The
energy buffering and transfer capacity into the cells is
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compromised in end-stage HF, partly due to a decrease in
CK activity (Khuchua et al. 1992; Saks et al. 1991) and a
diminution of creatine concentration (Kalsi et al. 1999;
Nascimben et al. 1996). These observations agree with
P NMR studies suggesting that a low PCr/ATP ratio is a
consequence of the creatine pool depletion.
Interestingly, despite different clinical manifestations,
end-stage HF from different etiology (dilated, hypertrophic,
or ischemic cardiomyopathies) seems to end up with the
same key changes in mitochondrial metabolism (Jarreta
et al. 2000; Kalsi et al. 1999; Scheubel et al. 2002; Sharov
et al. 2000), with the exception of the modification in the
ANT isoforms, which is specific to dilated cardiomyopathy
(Dörner and Schultheiss 2000).
The data on mitochondrial dysfunction acquired in
patients during the end-stage HF do not help in under-
standing the involvement of mitochondria in the develop-
ment of the disease. To determine whether alterations of
mitochondrial function plays a primary or a secondary role
in HF, we need to study patients at an early stage of HF or
with pathologies that lead to HF, but when compensatory
mechanisms still can maintain the cardiac output. Unfortu-
nately, such data are rare, mostly limited to very specific
enzymatic analysis and/or lack of an appropriate control
group (see Table 1). The varying methods used in different
laboratories make it difficult to compare the data between
studies. Whether the impairment of mitochondrial function
is primary or secondary in the development of HF remains
to be elucidated, as is the localization of the defect in
mitochondria.
Mitochondrial function in the prevention and treatment
cardiac diseases
A few studies have shown that some treatments for severe HF
improved mitochondrial function and structure, e.g., long-
term implantation of left ventricular assist devices improved
OXPHOS capacity (Lee et al. 1998), beta-blocker therapy
reversed part of the defect in ETC activity (Scheubel et al.
2002), and administering a beta-adrenoceptor agonist
increases cristae-to-matrix ratio and mitochondrial size
(Unverferth et al. 1980). An evolving trend in the treatment
of cardiac disease is the use of metabolic modulators,
including therapeutic targets aimed at improving mitochon-
drial energy production (reviewed by Murray et al. 2007) to
prevent or reverse the low energy status of the failing heart.
The application of those therapies requires a better under-
standing of cardiac mitochondrial function. Severe HF is
associated with a reversion of cardiac metabolism from a
use principally of free fatty acid metabolism in the healthy
heart to enhanced glucose oxidation in the failing heart
(Tuunanen et al. 2008). Glucose oxidation is favored during
hypoxia or ischemia, as a more oxygen-efficient substrate
(Abozguia et al. 2006). The administration of metabolic
regulators increasing carbohydrate oxidation, e.g., propionyl
L-carnitine, has been shown to improve ATP production in
the human heart (Bartels et al. 1992). There is, however, no
information on fatty acid oxidation by mitochondria in the
human heart, with the exception of measurements performed
on patients with coronary artery diseases, without controls
(Gellerich et al. 1994). One of the challenges for the future
management of cardiac disease will be to understand the
involvement of mitochondrial fatty acid oxidation in heart
failure. Also, targeting early events in mitochondrial
dysfunction may help to design therapies to prevent the
development of the disease before reaching an end-stage,
where multiple injuries make it very difficult to find an
ameliorative treatment.
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